The FDA approved lerodalcibep (Lerochol) injections for the treatment of elevated LDL cholesterol in adults, maker LIB Therapeutics announced. A third-generation PCSK9 inhibitor, lerodalcibep is ...

The highest dose of AstraZeneca’s small molecule halved levels of a type of “bad” cholesterol after 12 weeks, hitting the goal of a phase 2 trial in patients with a lipid disorder. The candidate in ...

NEW ORLEANS, LA—Use of enlicitide 20 mg, an oral PCSK9 inhibitor, significantly cut levels of LDL cholesterol and other atherogenic lipids in a large cohort of high-risk patients, results from the ...

Enlicitide, an oral PCSK9 inhibitor, reduced LDL-C by nearly 60% in adults with or at risk for ASCVD. The medication offers a daily oral alternative to injectable PCSK9 inhibitors, potentially ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

In a recent study published in PNAS, researchers from the University of Texas Southwestern Medical Center investigated cholesterol-mimetic compounds specifically binding and inhibiting Scap. Their ...

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a pair of phase 3 wins for enlicitide decanoate in patients with high ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a third-generation PCSK9 inhibitor to reduce cholesterol in certain high-risk patients. The ...

Having high blood cholesterol levels (hypercholesterolemia) is a risk factor for heart diseases like heart attacks and strokes because it can lead to plaque buildup, which can restrict blood flow. For ...